CONTROLLED SUBSTANCES ACT

Amendments

Drugs: clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), H5212, H5215, H5216, H5217, H5218 [15JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (H. Res. 934), H5113 [13JN]

——— prevent regulatory oversight from disrupting ability of emergency medical personnel to administer certain controlled substances (S. 916), S2881, S2882, S2884 [23MY]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (H. Res. 905), H4300 [22MY]

Bills and resolutions

DEA: allow certain community mental health centers to register as a clinic to allow telemedicine providers to prescribe controlled substances (see H.R. 5594), H3505 [24AP]

——— allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (see H.R. 5483), H3209 [12AP]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (see S. 2659, 2661), S2120 [12AP]

——— clarify process for denying, revoking, or suspending a registration to manufacture, distribute, or dispense a controlled substance (see H.R. 5267), H1542 [13MR]

——— deem drugs or other substances that act as opioid mu receptor antagonists to be in Schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 5298), H1651 [15MR]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse (see S. 2535), S1629 [12MR]

——— establish a national clearinghouse for all orders of controlled substances and require such orders pass through a database to identify suspicious orders and notify suppliers before orders are filled (see S. 3282), S5423 [26JY] (see H.R. 6600), H7723 [26JY]

——— improve systems for identifying diversion of controlled substances (see S. 2837), S2643 [14MY]

——— regulate selective androgen receptor modulators in the same manner as anabolic steroids (see S. 2742), S2391 [24AP]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (see S. 2838), S2678 [15MY] (see H.R. 6491), H7154 [24JY] (see H.R. 6779), H8169 [12SE]

——— restore ability to target pharmaceutical companies distributing opioids in certain communities by implementing a probable cause standard for intervention and striking the corrective action plan option (see S. 2493), S1338 [5MR] (see H.R. 6702), H7870 [5SE]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (see S. 2561), S1765 [15MR]

Dept. of Justice: prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (see H.R. 5050), H1212 [15FE]

——— require registration of tableting or encapsulating machines to assist law enforcement in identifying counterfeit pill makers (see S. 3281), S5423 [26JY] (see H.R. 6554), H7721 [26JY]

Dept. of Veterans Affairs: ensure that certain medical centers have physical locations for disposal of controlled substances medications (see H.R. 6848), H8737 [20SE]

Drugs: allow for more flexibility relative to medication-assisted treatment for opioid use disorders and protect confidentiality of substance use disorder patient records (see H.R. 5807), H3976 [15MY]

——— allow States, territories, and Indian tribes to control regulation of marijuana, remove industrial hemp from list of controlled substances, and maintain application of certain criminal offenses relative to marijuana (see S. 3032), S3293 [7JN] (see H.R. 6043), H4979 [7JN]

——— authorize employees of a hospice program to handle controlled substances in the residence of a deceased hospice patient to assist in disposal (see H.R. 5041), H1211 [15FE]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (see H. Res. 934), H5092 [12JN]

——— decriminalize marijuana, use tax revenues to assist certain small businesses, research effects on driving and health, restrict advertising to protect children, and expunge certain marijuana-related convictions (see S. 3174), S4734 [28JN]

——— improve medical research on marijuana (see H.R. 4825), H552 [18JA]

——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment (see S. 2711), S2321 [19AP]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues (see H.R. 6047), H4980 [7JN]

——— include fentanyl analogues under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 4922), H782 [5FE]

——— increase number of cannabis manufacturers registered under Controlled Substances Act for legitimate research purposes and allow VA health care providers to recommend federally-approved cannabis clinical trials (see H.R. 5634), H3705 [26AP]

——— increase penalties for fentanyl trafficking (see H.R. 6057), H5020 [8JN]

——— make marijuana legal at the Federal level, incentivize States to change marijuana laws that disproportionately impact minority communities, and allow retroactive review of marijuana sentences (see H.R. 4815), H477 [17JA]

——— modify offenses relative to fentanyl (see S. 2635), S2012 [9AP] (see H.R. 5459), H3095 [10AP]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders (see S. 2317), S253 [17JA]

——— provide for delivery of a controlled substance by a pharmacy to an administering practitioner (see H.R. 5202), H1476 [7MR]

FDA: increase authority to restrict entrance of illicit drugs into the U.S. through international mail facilities (see S. 2739), S2391 [24AP]

——— require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (see S. 3428), S6142 [12SE]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (see H. Res. 905), H4283 [21MY]

Health care facilities: authorize hospitals to dispose of controlled substances on behalf of patients who die at the hospital (see H.R. 6205), H5580 [22JN]

Letters

Right To Try Act: several organizations, H4358 [22MY]

Motions

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), H4363 [22MY]

Remarks in House

DEA: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment, H9248 [28SE]

——— allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (H.R. 5483), H5060, H5061 [12JN], E1537 [16NO]

——— clarify definition of ‘‘imminent danger to the public health or safety’’ to restore authority to suspend a pharmaceutical distributor’s license under certain circumstances (H.R. 4079), E888 [21JN]

Dept. of Justice: prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (H.R. 5050), E193 [15FE]

——— rescission of policy placing a low priority on Federal enforcement of marijuana laws in States with legalized marijuana, H21 [9JA], H96 [10JA], H420, H421, H471–H475 [17JA]

Drugs: authorize employees of a hospice program to handle controlled substances in the residence of a deceased hospice patient to assist in disposal (H.R. 5041), H5043–H5045 [12JN], H5163 [14JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), H5001 [8JN], H5099 [13JN], H5204–H5221 [15JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (H. Res. 934), H5107–H5115 [13JN], E841 [14JN]

——— define what constitutes a controlled substance analogue, clarify temporary import and distribution controls of certain synthetic drugs, and ensure Federal researchers can continue controlled substance research, H5215, H5216 [15JN]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, enable medicinal research, and allow prescription to veterans, H3501–H3503 [24AP]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, H5512, H5514 [22JN]

——— provide for legitimate use of medicinal marijuana in accordance with State laws, H21 [9JA], H471–H475 [17JA]

——— reschedule marijuana under the Controlled Substances Act, H474 [17JA]

——— specify the factors used to determine whether a controlled substance analogue is intended for human consumption, H5218–H5220 [15JN]

FDA: improve expanded access program to allow patients access to experimental life-saving drugs, H4364, H4365 [22MY]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (H.R. 878), H685 [30JA], H1647 [15MR]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), H485 [18JA], H4355–H4366 [22MY], H4682 [23MY], E751 [29MY]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (H. Res. 905), H4292–H4301 [22MY]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), motion to recommit, H4364, H4365 [22MY]

Remarks in Senate

Crime: reform and establish mandatory minimum sentences for certain offenses to provide more flexibility, strengthen penalties for violent crimes, review criminal justice system, and reduce recidivism among Federal inmates (S. 1917), S2676 [15MY]

DEA: allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals, S6472 [3OC]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (S. 2659), S2105 [12AP]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse, S6174 [17SE]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders, S6471 [3OC]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (S. 2838), S2680 [15MY], S3596 [11JN]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (S. 2561), S1766 [15MR]

Dept. of Justice: rescission of policy placing a low priority on Federal enforcement of marijuana laws in States with legalized marijuana, S33, S39–S42 [4JA]

Drugs: allow States, territories, and Indian tribes to control regulation of marijuana, remove industrial hemp from list of controlled substances, and maintain application of certain criminal offenses relative to marijuana, S7753 [18DE]

——— extend authority of nurse practitioners to provide medication-assisted treatment for opioid use disorders, S6163 [17SE]

——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment, S6164 [17SE]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues, S6473 [3OC]

——— prevent regulatory oversight from disrupting ability of emergency medical personnel to administer certain controlled substances (S. 916), S2882–S2884 [23MY]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, S6162 [17SE], S6463, S6469 [3OC]

FDA: require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (S. 3428), S6162 [17SE], S6463 [3OC]

Reports filed

Consideration of H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act: Committee on Rules (House) (H. Res. 934) (H. Rept. 115–751), H5092 [12JN]

Consideration of S. 204, Right To Try Act: Committee on Rules (House) (H. Res. 905) (H. Rept. 115–698), H4283 [21MY]

Opioid Quota Reform Act: Committee on the Judiciary (Senate) (S. 2535), S4035 [19JN]

Preventing Drug Diversion Act: Committee on the Judiciary (Senate) (S. 2837), S4035 [19JN]

Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act: Committee on the Judiciary (House) (H.R. 2851) (H. Rept. 115–713), H5020 [8JN]

Synthetic Abuse and Labeling of Toxic Substances (SALTS) Act: Committee on the Judiciary (Senate) (S. 207), S4035 [19JN]

Using Data To Prevent Opioid Diversion Act: Committee on the Judiciary (Senate) (S. 2838), S4035 [19JN]

Statements

Right To Try Act: Senator Johnson, H4360 [22MY]

Texts of

H. Res. 905, consideration of S. 204, Right To Try Act, H4292 [22MY]

H. Res. 934, consideration of H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act, H5107 [13JN]

H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act, H5212–H5215 [15JN]

H.R. 5041, Safe Disposal of Unused Medication Act, H5043 [12JN]

H.R. 5483, Special Registration for Telemedicine Clarification Act, H5060 [12JN]

S. 204, Right To Try Act, H4355 [22MY]

S. 916, Protecting Patient Access to Emergency Medications Act, S2882–S2884 [23MY]

S. 2535, Opioid Quota Reform Act, S1632 [12MR]

S. 3174, Marijuana Freedom and Opportunity Act, S4740 [28JN]